{"id":814802,"date":"2025-02-19T08:06:34","date_gmt":"2025-02-19T13:06:34","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/taysha-gene-therapies-to-release-full-year-2024-financial-results-and-host-conference-call-and-webcast-on-february-26\/"},"modified":"2025-02-19T08:06:34","modified_gmt":"2025-02-19T13:06:34","slug":"taysha-gene-therapies-to-release-full-year-2024-financial-results-and-host-conference-call-and-webcast-on-february-26","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/taysha-gene-therapies-to-release-full-year-2024-financial-results-and-host-conference-call-and-webcast-on-february-26\/","title":{"rendered":"Taysha Gene Therapies to Release Full-Year 2024 Financial Results and Host Conference Call and Webcast on February 26"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">DALLAS, Feb.  19, 2025  (GLOBE NEWSWIRE) &#8212; Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that it will report its financial results for the full-year ended December 31, 2024, and host a corporate update conference call and webcast on Wednesday, February 26, 2025, at 8:30 AM Eastern Time.<\/p>\n<p>\n        <strong>Conference Call Details<\/strong><br \/>\n        <br \/>\n        <strong><br \/>\n          <em>Wednesday, February 26, at\u00a08:30 AM Eastern Time\u00a0\/\u00a07:30 AM Central Time<\/em><br \/>\n        <\/strong><br \/>\n        <br \/>Toll Free: 877-407-0792<br \/>International: 201-689-8263<br \/>Conference ID: 13751800<br \/>Webcast: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=JqejvIAWlyt-nPp2MREexVikFaYdWNakpJvIU_re9TzhpJJttmlTkYgSD4nb8hCjbAnC5NtUuIaCSYO39XfbTvxp5uiltSHTaLQuZRnoAadRCo6bZsm0uFsuvY4ClVuP20XI8JTR5mF9Z6IVtz6x1bZeMmbVLQJhjyf7EbLdKB7EtC8S40Zv3bF2Ae1xOrTY\" rel=\"nofollow\" target=\"_blank\"><u>https:\/\/ir.tayshagtx.com\/news-events\/events-presentations<\/u><\/a><\/p>\n<p>\n        <strong>About Taysha Gene Therapies<\/strong><br \/>\n        <br \/>Taysha Gene Therapies\u00a0(Nasdaq: TSHA) is a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system. Its lead clinical program TSHA-102 is in development for Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. With a singular focus on developing transformative medicines, Taysha aims to address severe unmet medical needs and dramatically improve the lives of patients and their caregivers. The Company\u2019s management team has proven experience in gene therapy development and commercialization. Taysha leverages this experience, its manufacturing process and a clinically and commercially proven AAV9 capsid in an effort to rapidly translate treatments from bench to bedside. For more information, please visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=u4MMcCpiljuiq6uOxJwKhVveSLg17KBu8b2x6rwJ0GrSHBvgrKZbYdGkZ9aqX996v8YOqxthfcPvI-uZs7ECFJ6vl0F1zc_pd0FaHY6euJJBXRwI4mOE2qliOv-Jajl8huMPC46SVlW0rFNxk7Aw-FZqiXSlvBuuZzr0vAG0rJh_Oc8f-JX_uckgvxCjIYdH6x-TasHgtQajbOj_stgdaUs7PsrWQdlYjEg4DSuWh1fc04Laf3Q6kwlr3jBqMb4ABQlfM2Rg1M5_D1_8iAcXmA==\" rel=\"nofollow\" target=\"_blank\"><u>http:\/\/www.tayshagtx.com<\/u><\/a>.<\/p>\n<p>\n        <strong>Company Contact:<\/strong><br \/>\n        <br \/>Hayleigh Collins <br \/>Director, Head of Corporate Communications and Investor Relations<br \/>Taysha Gene Therapies, Inc.<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=je5Gfrmc1TvV9RPsi2zmB6caJpNiqvoeUZ2KgRAlxpRom4RFjXUS8O6FYVfLLgq2Es34p4z8fsSSsGZPvkdQKQ0jJL7DaDlxtqDo73PVyqY=\" rel=\"nofollow\" target=\"_blank\"><u>hcollins@tayshagtx.com<\/u><\/a><\/p>\n<p>\n        <strong>Media Contact:<\/strong><br \/>\n        <br \/>Carolyn Hawley<br \/>Inizio Evoke<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=FI0Urd-_reXEULNTSFoGjOcf3jTZMKJIFbNRFB_UA3XebJSR2RdF7JHWt4mMFUwUtdBU35lBOgiCXCPoiL2f4Rv6Afc62AEJiEB3KsuRBhK7mXQQ-cLkg7O5dzHepail\" rel=\"nofollow\" target=\"_blank\"><u>carolyn.hawley@inizioevoke.com<\/u><\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM1OTc0MSM2NzU0ODUyIzUwMDEwMzIzNw==\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/ODI3MGQ1YzUtNTU4Zi00NGZiLTg0NjUtODg4NTNlNWZjOGFjLTUwMDEwMzIzNw==\/tiny\/Taysha-Gene-Therapies-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>DALLAS, Feb. 19, 2025 (GLOBE NEWSWIRE) &#8212; Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that it will report its financial results for the full-year ended December 31, 2024, and host a corporate update conference call and webcast on Wednesday, February 26, 2025, at 8:30 AM Eastern Time. Conference Call Details Wednesday, February 26, at\u00a08:30 AM Eastern Time\u00a0\/\u00a07:30 AM Central Time Toll Free: 877-407-0792International: 201-689-8263Conference ID: 13751800Webcast: https:\/\/ir.tayshagtx.com\/news-events\/events-presentations About Taysha Gene Therapies Taysha Gene Therapies\u00a0(Nasdaq: TSHA) is a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system. &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/taysha-gene-therapies-to-release-full-year-2024-financial-results-and-host-conference-call-and-webcast-on-february-26\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Taysha Gene Therapies to Release Full-Year 2024 Financial Results and Host Conference Call and Webcast on February 26&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-814802","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Taysha Gene Therapies to Release Full-Year 2024 Financial Results and Host Conference Call and Webcast on February 26 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/taysha-gene-therapies-to-release-full-year-2024-financial-results-and-host-conference-call-and-webcast-on-february-26\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Taysha Gene Therapies to Release Full-Year 2024 Financial Results and Host Conference Call and Webcast on February 26 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"DALLAS, Feb. 19, 2025 (GLOBE NEWSWIRE) &#8212; Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that it will report its financial results for the full-year ended December 31, 2024, and host a corporate update conference call and webcast on Wednesday, February 26, 2025, at 8:30 AM Eastern Time. Conference Call Details Wednesday, February 26, at\u00a08:30 AM Eastern Time\u00a0\/\u00a07:30 AM Central Time Toll Free: 877-407-0792International: 201-689-8263Conference ID: 13751800Webcast: https:\/\/ir.tayshagtx.com\/news-events\/events-presentations About Taysha Gene Therapies Taysha Gene Therapies\u00a0(Nasdaq: TSHA) is a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system. &hellip; Continue reading &quot;Taysha Gene Therapies to Release Full-Year 2024 Financial Results and Host Conference Call and Webcast on February 26&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/taysha-gene-therapies-to-release-full-year-2024-financial-results-and-host-conference-call-and-webcast-on-february-26\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-02-19T13:06:34+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM1OTc0MSM2NzU0ODUyIzUwMDEwMzIzNw==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/taysha-gene-therapies-to-release-full-year-2024-financial-results-and-host-conference-call-and-webcast-on-february-26\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/taysha-gene-therapies-to-release-full-year-2024-financial-results-and-host-conference-call-and-webcast-on-february-26\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Taysha Gene Therapies to Release Full-Year 2024 Financial Results and Host Conference Call and Webcast on February 26\",\"datePublished\":\"2025-02-19T13:06:34+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/taysha-gene-therapies-to-release-full-year-2024-financial-results-and-host-conference-call-and-webcast-on-february-26\\\/\"},\"wordCount\":271,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/taysha-gene-therapies-to-release-full-year-2024-financial-results-and-host-conference-call-and-webcast-on-february-26\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM1OTc0MSM2NzU0ODUyIzUwMDEwMzIzNw==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/taysha-gene-therapies-to-release-full-year-2024-financial-results-and-host-conference-call-and-webcast-on-february-26\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/taysha-gene-therapies-to-release-full-year-2024-financial-results-and-host-conference-call-and-webcast-on-february-26\\\/\",\"name\":\"Taysha Gene Therapies to Release Full-Year 2024 Financial Results and Host Conference Call and Webcast on February 26 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/taysha-gene-therapies-to-release-full-year-2024-financial-results-and-host-conference-call-and-webcast-on-february-26\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/taysha-gene-therapies-to-release-full-year-2024-financial-results-and-host-conference-call-and-webcast-on-february-26\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM1OTc0MSM2NzU0ODUyIzUwMDEwMzIzNw==\",\"datePublished\":\"2025-02-19T13:06:34+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/taysha-gene-therapies-to-release-full-year-2024-financial-results-and-host-conference-call-and-webcast-on-february-26\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/taysha-gene-therapies-to-release-full-year-2024-financial-results-and-host-conference-call-and-webcast-on-february-26\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/taysha-gene-therapies-to-release-full-year-2024-financial-results-and-host-conference-call-and-webcast-on-february-26\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM1OTc0MSM2NzU0ODUyIzUwMDEwMzIzNw==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM1OTc0MSM2NzU0ODUyIzUwMDEwMzIzNw==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/taysha-gene-therapies-to-release-full-year-2024-financial-results-and-host-conference-call-and-webcast-on-february-26\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Taysha Gene Therapies to Release Full-Year 2024 Financial Results and Host Conference Call and Webcast on February 26\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Taysha Gene Therapies to Release Full-Year 2024 Financial Results and Host Conference Call and Webcast on February 26 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/taysha-gene-therapies-to-release-full-year-2024-financial-results-and-host-conference-call-and-webcast-on-february-26\/","og_locale":"en_US","og_type":"article","og_title":"Taysha Gene Therapies to Release Full-Year 2024 Financial Results and Host Conference Call and Webcast on February 26 - Market Newsdesk","og_description":"DALLAS, Feb. 19, 2025 (GLOBE NEWSWIRE) &#8212; Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that it will report its financial results for the full-year ended December 31, 2024, and host a corporate update conference call and webcast on Wednesday, February 26, 2025, at 8:30 AM Eastern Time. Conference Call Details Wednesday, February 26, at\u00a08:30 AM Eastern Time\u00a0\/\u00a07:30 AM Central Time Toll Free: 877-407-0792International: 201-689-8263Conference ID: 13751800Webcast: https:\/\/ir.tayshagtx.com\/news-events\/events-presentations About Taysha Gene Therapies Taysha Gene Therapies\u00a0(Nasdaq: TSHA) is a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system. &hellip; Continue reading \"Taysha Gene Therapies to Release Full-Year 2024 Financial Results and Host Conference Call and Webcast on February 26\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/taysha-gene-therapies-to-release-full-year-2024-financial-results-and-host-conference-call-and-webcast-on-february-26\/","og_site_name":"Market Newsdesk","article_published_time":"2025-02-19T13:06:34+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM1OTc0MSM2NzU0ODUyIzUwMDEwMzIzNw==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/taysha-gene-therapies-to-release-full-year-2024-financial-results-and-host-conference-call-and-webcast-on-february-26\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/taysha-gene-therapies-to-release-full-year-2024-financial-results-and-host-conference-call-and-webcast-on-february-26\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Taysha Gene Therapies to Release Full-Year 2024 Financial Results and Host Conference Call and Webcast on February 26","datePublished":"2025-02-19T13:06:34+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/taysha-gene-therapies-to-release-full-year-2024-financial-results-and-host-conference-call-and-webcast-on-february-26\/"},"wordCount":271,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/taysha-gene-therapies-to-release-full-year-2024-financial-results-and-host-conference-call-and-webcast-on-february-26\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM1OTc0MSM2NzU0ODUyIzUwMDEwMzIzNw==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/taysha-gene-therapies-to-release-full-year-2024-financial-results-and-host-conference-call-and-webcast-on-february-26\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/taysha-gene-therapies-to-release-full-year-2024-financial-results-and-host-conference-call-and-webcast-on-february-26\/","name":"Taysha Gene Therapies to Release Full-Year 2024 Financial Results and Host Conference Call and Webcast on February 26 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/taysha-gene-therapies-to-release-full-year-2024-financial-results-and-host-conference-call-and-webcast-on-february-26\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/taysha-gene-therapies-to-release-full-year-2024-financial-results-and-host-conference-call-and-webcast-on-february-26\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM1OTc0MSM2NzU0ODUyIzUwMDEwMzIzNw==","datePublished":"2025-02-19T13:06:34+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/taysha-gene-therapies-to-release-full-year-2024-financial-results-and-host-conference-call-and-webcast-on-february-26\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/taysha-gene-therapies-to-release-full-year-2024-financial-results-and-host-conference-call-and-webcast-on-february-26\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/taysha-gene-therapies-to-release-full-year-2024-financial-results-and-host-conference-call-and-webcast-on-february-26\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM1OTc0MSM2NzU0ODUyIzUwMDEwMzIzNw==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM1OTc0MSM2NzU0ODUyIzUwMDEwMzIzNw=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/taysha-gene-therapies-to-release-full-year-2024-financial-results-and-host-conference-call-and-webcast-on-february-26\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Taysha Gene Therapies to Release Full-Year 2024 Financial Results and Host Conference Call and Webcast on February 26"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/814802","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=814802"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/814802\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=814802"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=814802"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=814802"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}